

Datasheet: HCA237 BATCH NUMBER 1601

Description:	HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX)
Specificity:	OMALIZUMAB DRUG/TARGET COMPLEX
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD20760_hlgG1
Isotype:	lgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA				

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	IgG concentration 0.5 mg/ml
Immunogen	Omalizumab

Specificity

Human anti omalizumab, clone AbD20760_hlgG1 binds specifically to the omalizumab/lgE (drug/target) complex. The antibody does not recognize free omalizumab or free human lgE. It can be used in bioanalytical assays to detect bound omalizumab or

biosimilar products exclusively.

Clone AbD20760_hlgG1 can be used to develop a pharmacokinetic (PK) antigen capture assay to measure omalizumab captured via immobilized human IgE or to measure the level of drug/IgE complex in preclinical or clinical samples. This product is in a full immunoglobulin format and is available directly labeled with HRP. The antibody is also available in unlabeled Fab format (HCA238).

Omalizumab (brand name Xolair[®]) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (Fc ϵ RI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of Fc ϵ RI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of Fc ϵ RI on mast cells and basophils, providing additional clinical benefit.

View a summary of all anti-omalizumab antibodies

The monovalent intrinsic affinity of this antibody was measured as K_D = 0.58 nM by real time, label free molecular interaction analysis on immobilized omalizumab in complex with human IgE.

ELISA

This product may be used in a direct ELISA to detect the omalizumab/lgE complex or to detect omalizumab bound to immobilized lgE.

Protocol: PK antigen capture ELISA to measure bound drug exclusively

References

1. Harth, S. *et al.* (2019) Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics. <u>MAbs. 11 (1):</u> 178-190.

Storage

Store at +4°C or at -20°C if preferred.

Storage in frost-free freezers is not recommended.

This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee

12 months from date of despatch

Acknowledgements

Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.

	Xolair®is a registered trademark of Novartis.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA237
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u>

Related Products

Recommended Useful Reagents

HISPEC ASSAY DILUENT (BUF049A)

RECOMBINANT HUMAN IGE KAPPA (HCA190)

RECOMBINANT HUMAN IgE LAMBDA (HCA171)

HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX) (HCA238)

HUMAN ANTI OMALIZUMAB (HCA236)

HUMAN ANTI OMALIZUMAB (HCA235)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)

Product inquiries: www.bio-rad-antibodies.com/technical-support

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M371663:200612'

Printed on 14 Aug 2025

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint